Search results for " Crohn"

showing 10 items of 78 documents

Estudio del appel de los linfocitos gamma-delta en la enfermedad de Crohn

2015

La EII es un proceso inflamatorio crónico y recidivante de carácter sistémico que afecta predominantemente al tracto gastrointestinal, asociándose frecuentemente con manifestaciones extraintestinales . Existen dos subtipos principales de EII: la enfermedad de Crohn (EC) y la colitis ulcerosa (CU). La EC puede afectar cualquier parte del tracto digestivo, es de carácter transmural y suele afectar a individuos jóvenes, alternando periodos de remisión clínica y brotes de actividad. El control clínico de estos brotes recidivantes requiere el empleo de fármacos antiinflamatorios no exentos de efectos secundarios (corticoides, inmunosupresores, agentes biológicos etc.) siendo frecuente la necesid…

linfocitosinmunidadUNESCO::CIENCIAS MÉDICASenfermedad de crohninterleuquina 7linfocitos gamma-delta:CIENCIAS MÉDICAS [UNESCO]
researchProduct

COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Ita…

2021

The coronavirus disease 2019 (COVID-19) pandemic has not finished yet, and the most promising option towards its ending is widespread vaccination. Because patients with inflammatory bowel diseases (IBDs), namely Crohn’s disease (CD) and ulcerative colitis (UC), often require immune-modifying treatment, which might increase the risk of opportunistic infection,1 their vaccination history for several infectious diseases is routinely checked, and when inadequate, vaccination is performed at diagnosis or ideally before immune suppressive treatment is started.1 However, IBD patients were not found to be at an increased risk of developing COVID-19 or of experiencing a more severe disease course.2

medicine.medical_specialty2019-20 coronavirus outbreakCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)IBDBrief Report - ClinicalInternal medicinemedicineHumansImmunology and AllergyIn patientAcademicSubjects/MED00260SARS-CoV-2business.industryVaccinationGastroenterologyCOVID-19Inflammatory Bowel DiseasesInflammatory Bowel DiseasesCOVID-19 Vaccines HumanVaccinationIBD Crohn Ulcerative Colitis Vaccination Covid 19 Sars-Cov 2COVID-19; COVID-19 vaccine; IBD; vaccine hesitancyvaccine hesitancybusinessCOVID-19 vaccineInflammatory Bowel Diseases
researchProduct

Cytomegalovirus Pneumonia: A Possible Cause of Death in Patients With Crohn's Disease

2013

.

medicine.medical_specialtyCrohn's diseaseGastrointestinal agentCytomegalovirus pneumoniaHepatologyCrohn diseasebusiness.industryGastroenterologymedicine.diseaseCytomegalovirus Cytomegalovirus Infections ColitisGastroenterologyCytomegalovirus pneumonia Crohn’s diseaseAntibodies monoclonalInternal medicinemedicineIn patientbusinessCause of deathAmerican Journal of Gastroenterology
researchProduct

Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a…

2008

medicine.medical_specialtyCrohn's diseasetherapybusiness.industryGastroenterologyCompassionate Usemedicine.diseaseCertolizumabInfliximabClinical trialPharmacotherapyRefractoryCertolizumab Crohn's disease RefractoryInternal medicinemedicineImmunology and AllergyCertolizumab pegolbusinessmedicine.drug
researchProduct

Role of capsule endoscopy in pediatric Crohn's disease: A case report

2016

medicine.medical_specialtyHepatologyPediatric Crohn's diseaseCapsule endoscopylawbusiness.industryInternal medicineGastroenterologymedicinebusinessGastroenterologylaw.inventionDigestive and Liver Disease
researchProduct

Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of …

2017

Abstract The two main forms of intestinal bowel disease, namely ulcerative colitis and Crohn’s disease, are not curable but can be controlled by various medical therapies. The Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) has prepared clinical practice guidelines to help physicians prescribe corticosteroids and immunosuppressive drugs for these patients. The guidelines consider therapies that induce remission in patients with active disease as well as treatment regimens that maintain remission. These guidelines complement already existing guidelines from IG-IBD on the use of biological drugs in patients with inflammatory bowel diseases.

medicine.medical_specialtyIBDDiseaseGuidelineGuidelinesInflammatory bowel diseaseGastroenterologyBiological drugs03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesInternal medicineMedicalmedicineCorticosteroidCorticosteroidsHumansIn patient030212 general & internal medicineCorticosteroids; Crohn's disease; Guidelines; IBD; Immunosuppressors; Ulcerative colitis; Hepatology; GastroenterologySocieties MedicalCrohn's diseaseSettore MED/12 - GastroenterologiaUlcerative colitiHepatologybusiness.industryImmunosuppressorsRemission InductionGastroenterologyInflammatory Bowel Diseasesmedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisdigestive system diseasesClinical PracticeCrohn's diseaseUlcerative colitisItalyImmunosuppressorCorticosteroids; Crohn's disease; Guidelines; IBD; Immunosuppressors; Ulcerative colitis; Adrenal Cortex Hormones; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Italy; Remission Induction; Societies Medical030211 gastroenterology & hepatologybusinessSocietiesImmunosuppressive Agents
researchProduct

Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of…

2019

Patrizia Alvisi,1 Serena Arrigo,2 Salvatore Cucchiara,3 Paolo Lionetti,4 Erasmo Miele,5 Claudio Romano,6 Alberto Ravelli,7 Daniela Knafelz,8 Stefano Martelossi,9 Graziella Guariso,10 Salvatore Accomando,11 Giovanna Zuin,12 Costantino De Giacomo,13 Lucio Balzani,14 Monia Gennari,15 Marina Aloi3 On behalf of the SIGENP IBD Working Group 1Pediatric Gastroenterology Unit, Pediatric Department, Maggiore Hospital, Bologna, Italy; 2Pediatric Gastroenterology and Endoscopy Unit, G Gaslini Children’s Hospital, Genoa, Italy; 3Pediatric Gastroenterology and Liver Unit, Sapienza University of Rome, Rome, Italy; 4Gastroenterology and Nutrition Unit, Meyer Children’s Hospital, Florenc…

medicine.medical_specialtyPopulationadalimumab efficacy03 medical and health sciences0302 clinical medicineadalimumab efficacy; adalimumab safety; infliximab failure; pediatric crohn’s diseaseRheumatologyInternal medicinemedicineAdalimumabinfliximab failureImmunology and AllergyTargets and Therapy [Biologics]Pharmacology (medical)Adverse effecteducationPediatric gastroenterologyOriginal ResearchCrohn's diseaseeducation.field_of_studybusiness.industryAdalimumab efficacy; Adalimumab safety; Infliximab failure; Pediatric Crohn’s disease; Immunology and Allergy; Rheumatology; Oncology; Gastroenterology; Pharmacology (medical)Gastroenterologyadalimumab safetyHepatologymedicine.diseaseInfliximabOncology030220 oncology & carcinogenesisCohortpediatric Crohn’s disease030211 gastroenterology & hepatologybusinessmedicine.drugBiologics : Targets & Therapy
researchProduct

Inflammation and Aortic Stiffness: An Individual Participant Data Meta‐Analysis in Patients With Inflammatory Bowel Disease

2017

Background The recent finding that aortic pulse wave velocity ( aPWV ) is increased in patients with inflammatory bowel disease may explain why the cardiovascular risk is increased despite the low prevalence of traditional cardiovascular risk factors. We aimed to test whether inflammation is associated with aortic stiffening in this setting after adjustment for major confounders and to perform subgroup analyses. Methods and Results A systematic literature search for aPWV in inflammatory bowel disease was performed using PubMed, Scopus, Web of Science, and Google Scholar databases (last accessed May 7, 2017). Inclusion criterion was peer‐reviewed publications on clinical studies reporting o…

medicine.medical_specialtySettore MED/09 - Medicina Internapulse wave velocitycardiovascular complicationsBlood SedimentationPulse Wave Analysis030204 cardiovascular system & hematologyStandard scoreInflammatory bowel diseaseLeukocyte Count03 medical and health sciencesVascular Stiffness0302 clinical medicineCrohn DiseaseRisk FactorsInternal medicinemedicineHumansArterial stiffness; Cardiovascular complications; Crohn's disease; Inflammation; Pulse wave velocity; Ulcerative colitis; Cardiology and Cardiovascular Medicine030212 general & internal medicineulcerative colitisInflammationSystematic Review and Meta‐AnalysisCrohn's diseasemedicine.diagnostic_testbusiness.industryMeta Analysisinflammation aortic stiffnessPrognosismedicine.diseaseUlcerative colitisConfidence intervalCrohn's diseaseC-Reactive Proteinarterial stiffnessCardiovascular DiseasesMeta-analysisErythrocyte sedimentation rateMultivariate AnalysisHypertensionLinear ModelsPhysical therapyArterial stiffnessColitis UlcerativeInflammation MediatorsCardiology and Cardiovascular MedicinebusinessBiomarkersJournal of the American Heart Association
researchProduct

Investigational agents for Crohn's disease.

2010

IMPORTANCE OF THE FIELD: Increased understanding of the biological mechanisms of Crohn's disease has opened the door to a large number of new molecules; some of these are approved for clinical use, while others remain under evaluation. In this review, we examine the clinical efficacy of all the new drugs that have been evaluated in controlled trials in the last 12 years. AREAS COVERED IN THIS REVIEW: Anti-TNF therapy has been reviewed briefly, given the many comprehensive reviews on this topic; attention is focused mainly on the other biological therapies. In assessing the clinical efficacy of these molecules, we consider only the remission rate, as this is considered the most meaningful en…

medicine.medical_specialtybiological therapy. Crohn' s disease. Integrins.Probiotics.Small molecules.DiseaseAdaptive ImmunityReceptors Tumor Necrosis FactorCrohn DiseaseGastrointestinal AgentsmedicineHumansImmunologic FactorsPharmacology (medical)Clinical efficacyIntensive care medicineRandomized Controlled Trials as TopicPharmacologyMitogen-Activated Protein Kinase KinasesBiological therapiesCrohn's diseaseEverolimusEnd pointINVESTIGATIONAL AGENTSbusiness.industryRemission InductionAntibodies MonoclonalGeneral MedicineDrugs Investigationalmedicine.diseaseImmunity InnateImmunologyCytokinesRemission rateImmunotherapybusinessCell Adhesion Moleculesmedicine.drugExpert opinion on investigational drugs
researchProduct

MR Imaging of Perianal Crohn Disease: The Role of Contrast-enhanced Sequences

2017

The MR imaging protocol described by the authors includes contrast-enhanced T1-weighted imaging with fat saturation in all patients except those with poor renal function. Horsthuis et al demonstrated in 2009 the usefulness of contrast-enhanced MR imaging for determining disease activity. Contrast agent administration is also required in case of suspicion of neoplastic tissue complicating fistulas. The joint European Crohn’s and Colitis Organisation–European Society of Gastointestinal and Abdominal Radiology guidelines report that T2-weighted images and contrast-enhanced T1-weighted images are included in the MR imaging protocol for the evaluation of perianal CD. However, as we have demonstr…

medicine.medical_specialtybusiness.industrymedia_common.quotation_subjectMR STIRContrast MediaMagnetic Resonance ImagingMr imaging030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineText miningCrohn DiseasePerianal Crohn diseasemedicineHumansContrast (vision)030211 gastroenterology & hepatologyRadiology Nuclear Medicine and imagingRadiologybusinessmedia_common
researchProduct